Form 4: Centessa Pharma Exec Sells Shares for Tax

Centessa Pharmaceuticals plc's President of Orexin Program, Mario Alberto Accardi, reported a sale of 593 ordinary shares to cover tax obligations.

Summary

• Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc (CNTA), reported a transaction involving company shares.
• On November 1, 2025, 593 ordinary shares were disposed of at a price of $24.9 per share.
• This disposal was due to shares being withheld by the Issuer to cover tax withholding obligations related to the vesting of restricted share units.
• Following this transaction, Mr. Accardi beneficially owns 193,801 ordinary shares.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction (shares withheld for tax obligations) by an insider, which is neutral in terms of company sentiment.

Positives

• No direct positives for company performance or outlook are indicated by this routine tax-related transaction.

Negatives

• No direct negatives for company performance or outlook are indicated by this routine tax-related transaction.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing.

Future Outlook

NA

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically a tax-related share withholding. Such transactions are common across all industries for executives receiving equity compensation and do not typically reflect broader industry trends or competitive positioning.

Related Party Transactions

• The transaction involves an officer of the company and is a standard equity compensation-related event, not a related party transaction in the sense of unusual dealings.

Stakeholder Impact

• The impact on shareholders, employees, customers, suppliers, and creditors is minimal, as this is a routine, non-discretionary transaction for tax purposes by an executive.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Transaction, Share Sale, Tax Withholding, Mario Alberto Accardi, Restricted Share Units, 10b5-1 Plan